| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary target is IRE1α (inositol-requiring enzyme 1 alpha), a transmembrane serine/threonine kinase and endoribonuclease that is activated in response to ER stress. Kira8 binds to the ATP-binding pocket of IRE1α and inhibits its kinase and endoribonuclease activities, blocking XBP1 splicing and downstream signaling. This leads to inhibition of ER stress responses and reduced survival of cancer cells dependent on IRE1α.
|
|---|---|
| ln Vitro |
More effectively than KIRA6, Kira8 reverses GNF-2-promoted XBP1 splicing and lowers IRE1α-driven apoptosis in INS-1 cells. It also limits IRE1α oligomerization and effectively suppresses IRE1α RNase activity on XBP1 and Ins2 RNA [1].
Kira8 Hydrochloride is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC50 of 5.9 nM. Specific IC50 values for other IRE1α-mediated signaling pathways are not widely reported. |
| ln Vivo |
Intraperitoneal injection of KIRA8 (50 mg/kg; daily; for 35 days) in male Ins2+/Akita mice markedly reduced hyperglycemia within few weeks [1]. Treatment of prediabetic NOD mice with Kira8 (50 mg/kg; i.p.; once daily) for one week led in a substantial reduction in islet XBP1 splicing and TXNIP mRNA, and retained Ins1/Ins2, BiP, and MANF mRNA [1].
In vivo, Kira8 Hydrochloride is a potential therapeutic agent for cancer and inflammatory diseases. It would be expected to show efficacy in animal models of IRE1α-dependent diseases. Typical doses and outcome measures are not widely reported. |
| Enzyme Assay |
IRE1α endoribonuclease activity assays use recombinant IRE1α and a fluorescently labeled XBP1 RNA substrate. Kira8 is incubated with the enzyme and substrate. Cleavage of the substrate is measured by fluorescence. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell-based assays use cancer cell lines (e.g., multiple myeloma, glioblastoma). Cells are treated with Kira8 Hydrochloride (0.01-10 µM) for 24-72 hours. XBP1 splicing is measured by RT-PCR. Cell viability is measured by MTT assay. Apoptosis is assessed by caspase-3 activation.
|
| Animal Protocol |
Animal/Disease Models: Male Ins2+/Akita mice [1]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; daily; continued for 35 days Experimental Results: Hyperglycemia was Dramatically diminished after a few weeks. In vivo, Kira8 Hydrochloride would be tested in mouse xenograft models. A typical protocol would involve intraperitoneal or oral administration (10-50 mg/kg) in mice with tumor xenografts. Tumor volume would be measured. XBP1 splicing in tumor tissue would be assessed by RT-PCR. |
| References |
| Molecular Formula |
C31H30CL2N6O3S
|
|---|---|
| Molecular Weight |
637.579303264618
|
| Exact Mass |
636.147
|
| CAS # |
2250019-92-0
|
| Related CAS # |
Kira8;1630086-20-2
|
| PubChem CID |
134160238
|
| Appearance |
White to yellow solid
|
| tPSA |
127
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
43
|
| Complexity |
971
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=C(C2=C(C=C1)C(=CC=C2)NS(=O)(=O)C3=CC=CC=C3Cl)OC4=C(C=CC=N4)C5=NC(=NC=C5)N[C@H]6CCCNC6.Cl
|
| InChi Key |
CNWIPRHGMZTPSB-BOXHHOBZSA-N
|
| InChi Code |
InChI=1S/C31H29ClN6O3S.ClH/c1-20-13-14-22-23(8-4-11-27(22)38-42(39,40)28-12-3-2-10-25(28)32)29(20)41-30-24(9-6-17-34-30)26-15-18-35-31(37-26)36-21-7-5-16-33-19-21;/h2-4,6,8-15,17-18,21,33,38H,5,7,16,19H2,1H3,(H,35,36,37);1H/t21-;/m0./s1
|
| Chemical Name |
2-chloro-N-[6-methyl-5-[3-[2-[[(3S)-piperidin-3-yl]amino]pyrimidin-4-yl]pyridin-2-yl]oxynaphthalen-1-yl]benzenesulfonamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 100 mg/mL (~156.8 mM)
DMSO: ~50 mg/mL (~78.4 mM; with ultrasonication) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5684 mL | 7.8422 mL | 15.6843 mL | |
| 5 mM | 0.3137 mL | 1.5684 mL | 3.1369 mL | |
| 10 mM | 0.1568 mL | 0.7842 mL | 1.5684 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.